DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tesaglitazar
Tesaglitazar
Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
NPY1R-Targeted Peptide-Mediated Delivery of a Dual PPAR&Alpha
Tot-JNK 18S Patent Application Publication Mar
Oral Anti-Diabetic Agents-Review and Updates
Stembook 2018.Pdf
Current Pharma Research ISSN: 2230-7842 CPR 3(2), 2013, 846-854
Product Monograph
Dual Pparα/Γ Activation Inhibits SIRT1-Pgc1α Axis and Causes Cardiac Dysfunction
Peroxisome Proliferator Activated Receptors
(12) Patent Application Publication (10) Pub. No.: US 2010/013.6614 A1 Luo Et Al
PPAR Agonists Regulate Brain Gene Expression: Relationship to Their 66 2 67 3 Effects on Ethanol Consumption 68 4 69 A, B, * A, B a a 5 Q2 Laura B
Combination Treatment with Pioglitazone and Fenofibrate
Targeting Ppars
Saroglitazar in Patients with Non-Alcoholic Fatty Liver Disease And
Review Article Idealized Pparγ-Based Therapies: Lessons from Bench and Bedside
Drugs in Pipeline for Type-2 Diabetes R Mahajan, K Gupta
Dual Peroxisome-Proliferator-Activated-Receptor-Α/Γ Activation Inhibits SIRT1-Pgc1α Axis and Causes Cardiac Dysfunction
Top View
Chembl an Open Data Resource of Medicinal Chemistry and Patent Data John P
(PPAR) Agonists in Substance Use Disorders: a Synthesis of Preclinical and Human Evidence
Oral Antidiabetic Agents-Review and Updates 2 3 Patience O
Canagliflozin/Metformin FDC (Vokanamet
Novel Treatments for Type 2 Diabetes
Past and Current Perspective on New Therapeutic Targets for Type-II Diabetes
The Endocannabinoid System and Ppars: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation
PPAR-Mediated Toxicology and Applied Pharmacology
Original Article
Favorable Cardiovascular Effects of Pioglitazone: a Meta-Analysis
Ep 1 599 469 B1
Supplementary Materials: Building and Testing Pparγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain
Pleiotropic Effects of Glitazones: a Double Edge Sword?
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Selective Activation of PPAR and Pparγ
Biocatalyzed Synthesis of Antidiabetic Drugs: a Review
Telomeres and Peroxisome Proliferator-Activated Receptor Gamma in the Development of Human Breast Cancer
Wo 2010/045656 A2
Ppars and Myocardial Infarction
Safety Issues Hamper Dual PPAR Agonists: Is Partial Antagonism The
Effect of a Dual PPAR Α/Γ Agonist on Insulin Sensitivity in Patients Of
Saroglitazar, a Novel Cardiometabolic Agent for Diabetic Dyslipidemia – a Review
Saroglitazar: India's Answer to Diabetic Dyslipidemia
Safety and Efficacy Modelling in Anti-Diabetic Drug Development
A Narrative Review of Potential Future Antidiabetic Drugs:Should We Expect More?
Saroglitazar
Diabetic Dyslipidemia
Comparative Transcriptional Network Modeling of Three PPAR-#/# Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
And PPAR Induces Neoangiogenesis Through a Vascular